• NEWS & PUBLICATIONS
  • News and Media
  • Newsletters
  • Journals
  • Books
• MEMBERSHIP
  • Join/Renew
  • Benefits
  • Categories
  • Download a Member Application
  • Grants, Awards, and Scholarships
  • Access the Phantom Analysis Toolkit
  • Membership Directory
  • Chapters
  • Centers of Excellence
  • Councils
  • Member Spotlight
  • Women in Nuclear Medicine
  • SNMMI Fellow
  • SNMMI-TS Fellow
  • Council and Center Internships
• EDUCATION
  • Learning Center
  • Webinars
• MEETINGS & EVENTS
  • Calendar of Events
  • Webinars
  • 2024 Annual Meeting
  • 2024 Therapeutics Conference
  • 2024 Mid-Winter Meeting
  • Nuclear Medicine & Molecular Imaging Week
• ADVOCACY
  • Coding & Reimbursement
  • Legislative Efforts
  • Government Relations News
  • Radiopharmaceutical Supply News
  • USP 825
  • Technologist State Issues
  • Position Statements
  • FDA PET Drug Manufacturing Q&A
• EVIDENCE & QUALITY
  • Clinical Guidelines and AUC
  • Quality
  • Quality and Patient Safety
  • Dose Optimization
  • About Quality & Practice
  • Dosimetry
• RESEARCH
  • Clinical Trials Network
  • Radiopharmaceutical Therapy Central
  • Radiopharmaceutical Therapy Centers of Excellence
  • Preclinical Imaging
  • Nuclear Medicine Clinical Trial Group, LLC
  • Research: Learn More
• ABOUT SNMMI
  • Strategic Plan
  • Bylaws & Procedures
  • Governance - SNMMI
  • Governance - SNMMI-TS
  • History
  • Grants, Awards, and Scholarships
  • Career Center
  • About Nuclear Medicine & Molecular Imaging
  • International Collaboration
  • Outreach
  • Support SNMMI
  • Contact Us

Pathways January 2019

Volume 9, Issue 1

18F Flurpiridaz Shows Promise as a Diagnostic Imaging Agent for CAD

• Download: 2019 Pathways

Download Acrobat Reader